UPDATE 1-BioMarin's Morquio A drug confers "modest" benefit -FDA review

Nov 15 (Reuters) - An experimental drug to treat a rare genetic disorder that causes skeletal malformation and a host of related lung, eye, ear and heart problems confers "modest" benefit, according to an initial review by the U.S. Food and Drug Administration.